Alanzi Abdullah R, Shahat Abdelaaty A, Alhaidhal Bayan Abdullah, Aloatibi Raghad Mohammad
Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
PLoS One. 2025 May 13;20(5):e0323781. doi: 10.1371/journal.pone.0323781. eCollection 2025.
Rho-associated protein kinase 2 (ROCK2) is a serine/threonine kinase that is crucial for regulating various physiological processes and is part of the Rho-associated coiled-coil kinase family. The dysregulation of ROCK2 has been associated with a range of diseases, making it a promising target for therapy. In this study, a chemical feature-based pharmacophore model was developed on the co-crystal ligand (5YS) of ROCK2 to conduct the virtual screening of ZINC database, resulting in 4809 hits that were further subjected to molecular docking to find the binding affinities with ROCK2 protein. The binding affinities of the hits were analyzed and compounds in the range of -11.55 to -9.91 kcal/mol were selected for further analysis. The ADMET analysis identified two promising compounds, whose binding stability with the ROCK2 protein was further evaluated using molecular dynamics (MD) simulations. Simulation results revealed that the selected compounds remained closely bound to protein indicating that they can act as lead compounds to control the biological activity of ROCK2. However, further in vitro investigation is required to test the biological efficacy of the reported compounds.
Rho相关蛋白激酶2(ROCK2)是一种丝氨酸/苏氨酸激酶,对调节各种生理过程至关重要,是Rho相关卷曲螺旋激酶家族的一部分。ROCK2的失调与一系列疾病有关,使其成为一个有前景的治疗靶点。在本研究中,基于ROCK2的共晶体配体(5YS)开发了一种基于化学特征的药效团模型,用于对ZINC数据库进行虚拟筛选,得到4809个命中结果,这些结果进一步进行分子对接以寻找与ROCK2蛋白的结合亲和力。分析了命中结果的结合亲和力,并选择结合亲和力在-11.55至-9.91千卡/摩尔范围内的化合物进行进一步分析。ADMET分析确定了两种有前景的化合物,使用分子动力学(MD)模拟进一步评估了它们与ROCK2蛋白的结合稳定性。模拟结果表明,所选化合物与蛋白保持紧密结合,表明它们可作为先导化合物来控制ROCK2的生物学活性。然而,需要进一步的体外研究来测试所报道化合物的生物学功效。